Skip to main content
. 2020 Jan 19;7(1):e000947. doi: 10.1136/openhrt-2018-000947

Table 4.

The individual components of MACE and clinical outcomes at 24 months

Provisional side branch stenting (Simple) Two-stent technique (Complex) Risk difference
(95% CI)
P value
Events at 6 months Follow-up in 220 patients Follow-up in 228 patients
MACE 12 (5.5%) 5 (2.2%) 3.2% (−0.2 to 6.8) 0.07
All-cause mortality 0 (0%) 1 (0.4%) −0.4% (−1.3 to 0.4) 0.33
Cardiac mortality 0 (0%) 0 (0%) 0.0% (0.0 to 0.0) 1.00
Myocardial infarction* 6 (2.7%) 3 (1.3%) 1.4% (−1.2 to 4.0) 0.29
Target-lesion revascularisation 9 (4.1%) 4 (1.8%) 2.3% (−0.8 to 5.5) 0.14
Target-vessel revascularisation 10 (4.6%) 4 (1.8%) 2.8% (−0.4 to 6.0) 0.11
Definite stent thrombosis 2 (0.9%) 2 (0.9%) 0.0% (−1.7 to 1.8) 0.97
Events at 24 months† Follow-up in 218 patients Follow-up in 228 patients HR(95% CI) P value
MACE 12.9% (28) 8.4% (19) 0.63 (0.35 to 1.13) 0.12
All-cause mortality 2.3% (5) 2.2% (5) 0.94 (0.28 to 3.31) 0.94
Cardiac mortality 0.9% (2) 0.9% (2) 0.96 (0.13 to 6.8) 0.96
Myocardial infarction* 5.1% (11) 3.1% (7) 0.60 (0.23 to 1.55) 0.30
Target-lesion revascularisation 9.2% (20) 6.2% (14) 0.66 (0.33 to 1.30) 0.23
Target-vessel revascularisation 10.5% (23) 6.6% (15) 0.61 (0.32 to 1.17) 0.13
Risk difference (95% CI)
CCS class ≥2 angina‡ 8 (3.9%) 9 (4.1%) −0.2% (−4.0 to 3.4) 0.89
Stent thrombosis‡
 Definite, any (0–2 years) 3 (1.4%) 3 (1.3%) 0.1% (−2.0 to 2.2) 0.96
 Definite, acute (0–1 day) 1 (0.5%) 1 (0.4%) 0.0% (−1.2 to 1.3) 0.98
 Definite, subacute (2–30 days) 1 (0.5%) 1 (0.4%) 0.0% (−1.2 to 1.3) 0.98
 Definite, late (1–12 months) 0 (0.0%) 0 (0.0%) 0.0% (0.0 to 0.0)
 Definite, very late (12–24 months) 1 (0.5%) 1 (0.4%) 0.0% (−1.2 to 1.3) 0.98
 Definite or probable, any (0–2 years) 4 (1.8%) 3 (1.3%) 0.5% (−1.7 to 2.8) 0.66
 Definite, prob. or poss., any (0–2 years) 6 (2.8%) 5 (2.2%) 0.6% (−2.3 to 3.4) 0.70

*Non-procedure related. Values are n (%).

†Twenty-four month results are given as Kaplan-Meier estimates and (n).

‡Results are given as n (%), risk difference and 95% CI.

MACE, major adverse cardiac events.